Real world survival outcomes in patients with high risk stage II colon cancer at a Beijing Cancer Hospital

被引：1
|
作者：
Wu, Aiwen
Chen, Peng-ju
Li, Tian-le
Dankwa-Mullan, Irene
Sun, Ting-Ting
Rhee, Kyu
机构：
[1] Beijing Canc Hosp, Peking Univ Canc Hosp & Inst, Beijing, Peoples R China
[2] Qingdao Baheal Intelligent Technol Co LTD, Qingdao, Peoples R China
[3] IBM Watson Hlth, Bethesda, MD USA
[4] IBM Watson Hlth, Southbury, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e15670
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15670
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Clinical Decision Support for High-Risk Stage II Colon Cancer: A Real-World Study of Treatment Concordance and Survival
    Chen, Peng-ju
    Li, Tian-le
    Sun, Ting-ting
    Willis, Van C.
    Roebuck, M. Christopher
    Bravata, Dena M.
    Liu, Xin-zhi
    Arriaga, Yull E.
    Dankwa-Mullan, Irene
    Wu, Ai-wen
    DISEASES OF THE COLON & RECTUM, 2020, 63 (10) : 1383 - 1392
  • [2] The effect of gaps in chemotherapy on survival in patients with high-risk stage II and stage III colon cancer
    Sada, Yvonne
    Duan, Zhigang
    El-Serag, Hashem
    Davila, Jessica
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (34)
  • [3] IDENTIFICATION OF HIGH-RISK PATIENTS IN STAGE II COLON CANCER
    Lanza, Giovanni
    Gafa, Roberta
    Santini, Alessandra
    Maestri, Iva
    Guerzoni, Laura
    Liboni, Alberto
    Azzena, Gianfranco
    Lelli, Giorgio
    Cavazzini, Luigi
    ANNALS OF ONCOLOGY, 2004, 15 : 66 - 66
  • [4] Biomarker for high-risk patients with stage II colon cancer
    Watanabe, Toshiaki
    LANCET ONCOLOGY, 2013, 14 (13): : 1247 - 1248
  • [5] EFFECTIVENESS OF ADJUVANT CHEMOTHERAPY ON SURVIVAL OF ELDERLY PATIENTS WITH HIGH RISK STAGE II COLON CANCER.
    Kim, M.
    Kim, C.
    Bae, S.
    Hur, H.
    Min, B.
    Baik, S.
    Lee, K.
    Kim, N.
    DISEASES OF THE COLON & RECTUM, 2013, 56 (04) : E215 - E215
  • [6] Survival and patient-reported outcomes of real-world patients with high-risk stage II and stage III colon cancer after 3 versus 6 months of adjuvant CAPOX.
    Franken, Ingrid A.
    van der Baan, Frederieke H.
    Vink, Geraldine R.
    May, Anne Maria
    van Grevenstein, Wilhelmina M. U.
    Koopman, Miriam
    Roodhart, Jeanine
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] Risk Stratification in Patients with Stage II Colon Cancer
    Amri, Ramzi
    England, Jonathan
    Bordeianou, Liliana G.
    Berger, David L.
    ANNALS OF SURGICAL ONCOLOGY, 2016, 23 (12) : 3907 - 3914
  • [8] Risk Stratification in Patients with Stage II Colon Cancer
    Ramzi Amri
    Jonathan England
    Liliana G. Bordeianou
    David L. Berger
    Annals of Surgical Oncology, 2016, 23 : 3907 - 3914
  • [9] Survival and patient-reported outcomes of real-world high-risk stage II and stage III colon cancer patients after reduction of adjuvant CAPOX duration from 6 to 3 months
    Franken, Ingrid A.
    van der Baan, Frederieke H.
    Vink, Geraldine R.
    May, Anne M.
    van Grevenstein, Wilhelmina M. U.
    Koopman, Miriam
    Roodhart, Jeanine M. L.
    EUROPEAN JOURNAL OF CANCER, 2024, 208
  • [10] Identification of high risk stage II colon cancer patients for adjuvant therapy
    Quah, H.
    Wong, W.
    Shia, J.
    Schrag, D.
    Guillem, J.
    Paty, P.
    Temple, L.
    Weiser, M.
    DISEASES OF THE COLON & RECTUM, 2007, 50 (05) : 710 - 710
12345